Article PDF
Avoid common mistakes on your manuscript.
References
Cai, Q., Huang, D., Yu, H., Zhu, Z., Xia, Z., Su, Y., Li, Z., Zhou, G., Gou, J., Qu, J., et al. (2020). COVID-19: Abnormal liver function tests. J Hepatol 73, 566–574.
Crisan, D., Avram, L., Grapa, C., Dragan, A., Radulescu, D., Crisan, S., Grosu, A., Militaru, V., Buzdugan, E., Stoicescu, L., et al. (2021). Liver injury and elevated FIB-4 define a high-risk group in patients with COVID-19. J Clin Med 11, 153.
Graupera, I., Thiele, M., Serra-Burriel, M., Caballeria, L., Roulot, D., Wong, G.L.H., Fabrellas, N., Guha, I.N., Arslanow, A., Expósito, C., et al. (2021). Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol, doi: https://doi.org/10.1016/j.cgh.2021.12.034.
Li, J., Tian, A., Zhu, H., Chen, L., Wen, J., Liu, W., and Chen, P. (2022). Mendelian randomization analysis reveals no causal relationship between nonalcoholic fatty liver disease and severe COVID-19. Clin Gastroenterol Hepatol, doi: https://doi.org/10.1016/j.cgh.2022.01.045.
Li, Y., Regan, J., Fajnzylber, J., Coxen, K., Corry, H., Wong, C., Rosenthal, A., Atyeo, C., Fischinger, S., Gillespie, E., et al. (2021). Liver fibrosis index FIB-4 is associated with mortality in COVID-19. Hepatol Commun 5, 434–445.
Romero-Cristóbal, M., Clemente-Sánchez, A., Piñeiro, P., Cedeño, J., Rayón, L., Del Río, J., Ramos, C., Hernández, D.A., Cova, M., Caballero, A., et al. (2021). Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients. Therap Adv Gastroenterol 14, 175628482110234.
Sterling, R.K., Shin, D., Shin, Y., French, E., Stevens, M.P., Bajaj, J.S., DeWit, M., and Sanyal, A.J. (2021). Fibrosis-4 predicts the need for mechanical ventilation in a national multiethnic cohort of corona virus disease 2019. Hepatol Commun 5, 1605–1615.
Targher, G., Mantovani, A., Byrne, C.D., Wang, X.B., Yan, H.D., Sun, Q.F., Pan, K.H., Zheng, K.I., Chen, Y.P., Eslam, M., et al. (2020). Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut 69, 1545–1547.
Wang, Y., Liu, S., Liu, H., Li, W., Lin, F., Jiang, L., Li, X., Xu, P., Zhang, L., Zhao, L., et al. (2020). SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 73, 807–816.
Wijarnpreecha, K., Ungprasert, P., Panjawatanan, P., Harnois, D.M., Zaver, H.B., Ahmed, A., and Kim, D. (2021). COVID-19 and liver injury: a meta-analysis. Eur J Gastroenterol Hepatol 33, 990–995.
Acknowledgements
This work was supported by grant from Research Start-up Fund in Changning Maternity and Infant Health Hospital (2021Y-15).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Compliance and ethics The author(s) declare that they have no conflict of interest.
Supplementary Material
Rights and permissions
About this article
Cite this article
Tang, K., Wang, L., Shen, L. et al. Quantitative assessment of fibrosis-4 score and adverse clinical outcomes in patients with COVID-19. Sci. China Life Sci. 65, 2560–2563 (2022). https://doi.org/10.1007/s11427-021-2138-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-021-2138-7